Halozyme Therapeutics HALO Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue from Contract with Customer, Excluding Assessed Tax by Product | ||||||
| Bulk rHuPH20 sales | $73.5M+46.3% | $50.24M+54.6% | $32.49M+39.6% | $23.27M-13.9% | $27.03M+37.2% | |
| Device licensing and development revenue | $5.6M+4.1% | $5.38M+34.6% | $4M-1.8% | $4.07M+19.4% | $3.41M+5.7% | |
| Device partnered product sales | $15.05M+17.1% | $12.86M+35.4% | $9.5M-19.4% | $11.79M-19.7% | $14.68M+18.7% | |
| Proprietary product sales | $41.87M-29.7% | $59.57M+14.0% | $52.24M+12.5% | $46.45M+27.8% | $36.34M-23.2% | |
| Royalties | $240.68M-6.7% | $257.97M+9.3% | $236.04M+14.8% | $205.64M+22.3% | $168.19M-1.3% | |
| Sales-based milestones | $0-100% | $25M+25.0% | $20M+100% | $10M-33.3% | $15M-50.0% | |
| Upfront license and target nomination fees | $0-100% | $18.25M— | $0— | $0-100% | $220K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Halozyme Therapeutics break its business down?
- Halozyme Therapeutics (HALO) reports revenue from contract with customer, excluding assessed tax by product across 7 parts — Bulk rHuPH20 sales, Device licensing and development revenue, Device partnered product sales, Proprietary product sales and Royalties. Each is extracted from the segment footnotes and tracked over time.
- Where does Halozyme Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Halozyme Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
